Chloramphenicol Tablets

The main ingredient of this product is chloramphenicol.

This product is a sugar-coated tablet or a film-coated tablet. After removing the coating, it appears white or slightly yellow-green.

Oral administration: Adults: 1.5-3g per day, divided into 3-4 doses; Children: 25-50mg/kg per day, divided into 3-4 doses according to body weight; Newborns: no more than 25mg/kg per day, divided into 4 doses.

1. Toxic reaction to the hematopoietic system is the most serious adverse reaction of chloramphenicol. There are two different forms of manifestation: (1) Dose-related reversible bone marrow suppression, which is common in patients with blood drug concentrations exceeding 25 mg/L. The clinical manifestations are anemia, and may be accompanied by leukopenia and thrombocytopenia. (2) Bone marrow toxicity reactions that are unrelated to dose, often manifested as severe, irreversible aplastic anemia. Patients with aplastic anemia may have a latent period of several weeks to several months, and it is not easy to detect early. Its clinical manifestations include bleeding tendency caused by thrombocytopenia, such as petechiae, ecchymoses and epistaxis, and signs of infection caused by granulocytopenia, such as high fever, sore throat, jaundice, etc. The vast majority of aplastic anemia occurs after oral chloramphenicol. 2. Hemolytic anemia, which can occur in some congenital glucose-

It is contraindicated for those who are allergic to this product.

1. Antiepileptic drugs (hydantoins). Chloramphenicol can inhibit the activity of liver cell microsomal enzymes, resulting in reduced metabolism of this type of drug, or chloramphenicol can replace the serum protein binding site of this type of drug, which can enhance the effect of the drug or increase its toxicity. Therefore, when used with chloramphenicol or after it, the dosage of this type of drug must be adjusted. 2. When used with hypoglycemic drugs (such as tolbutamide), the hypoglycemic effect can be enhanced due to the replacement of protein binding sites, so the dosage of this type of drug needs to be adjusted. The non-ionic binding characteristics of glipizide and glyburide make them less affected than other oral hypoglycemic drugs, but caution is still required when used together. 3. Long-term oral contraceptives containing estrogen, such as taking chloramphenicol at the same time, can reduce the reliability of contraception and increase menstrual bleeding. 4

Keep sealed.

0.25g*100g

36 months

Shandong Renhe Pharmaceutical Co., Ltd.

• Founded in:

  2001-10-10

• Address:

  No. 1, Renhe Road, Home Appliance Industrial Park, Lizhuang Town, Tancheng County, Shandong Province

• Tax NO.:

  91371322732596671Q

• Registered Funds:

  95.4682 million yuan

• Email:

  Log in to view